1. Generics Bulletin
  2. >>Legal & IP

Vietnam Commits To Patent Extensions and Data Exclusivity Via EU Trade Deal

 
• By Aidan Fry

Two-year patent-term extensions and five-year data exclusivity are on the cards for Vietnam under the terms of a trade deal it has negotiated with the European Commission.

Vietnam_EU_Flags
Vietnam is set to implement intellectual-property pharma protections under a trade deal with the EU • Source: Shutterstock

Vietnam has committed to extending patent terms for up to two years and granting five-year data exclusivity as part of a free trade agreement and investment protection agreement it signed with the European Commission on 30 June. The deal will now go to Vietnam’s national assembly, as well as to the European Parliament, for ratification.

An intellectual-property chapter to the agreement signed in Hanoi, Vietnam, includes an article on administrative authorization procedures such as marketing...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Generics Bulletin

Pipeline And Parent: Meitheal CEO Shea Talks Paclitaxel And What’s Next

 
• By Dean Rudge

In an exclusive interview, Meitheal Pharmaceuticals CEO Tom Shea discusses the company’s oncology strategy following the recent launch of generic Abraxane, alongside discussion of complex injectables, the biosimilars pipeline, and how $300m in backing is fueling the company's next phase of growth.

Endo Offloads Paladin As Shareholders Approve Mallinckrodt Merger

 
• By Dave Wallace

As it prepares to complete its $6.7bn merger with Mallinckrodt, Endo has divested its International Pharmaceuticals business – consisting primarily of Canadian specialty firm Paladin Pharma – to Knight Therapeutics.

Canada Joins Global Push To Drop Costly Clinical Trials For Biosimilars

 
• By Neena Brizmohun

Health Canada’s proposal to no longer require biosimilar manufacturers to prove the safety and efficacy of their product through Phase III clinical trials marks a pivotal change in Canada’s regulatory approach.